Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142922 | 0.85 | QTRT1 (0.42) | QTRT1PNPDYRK1ATYMSMAPT | |
| SCHEMBL1919722 | 0.77 | — | — | |
| SCHEMBL5898 | 0.77 | ALDH1A1 (0.31) | ALDH1A1MEN1HPGDKMT2ATP53 | |
| 7-Deazaguanine SCHEMBL26412 | 0.68 | PNP (0.38) | QTRT1PNPDYRK1ATYMSMAPT | |
| SCHEMBL18525722 | 0.67 | XDH (0.40) | QTRT1PNPDYRK1ATYMSMAPT | |
| SCHEMBL8885137 | 0.67 | PNP (0.41) | QTRT1PNPDYRK1AMAPTCDK1 | |
| SCHEMBL6055297 | 0.67 | PNP (0.41) | QTRT1PNPDYRK1AMAPTCDK1 | |
| SCHEMBL6322310 | 0.67 | PNP (0.41) | QTRT1PNPDYRK1ATYMSMAPT | |
| SCHEMBL10964765 | 0.66 | PNP (0.36) | QTRT1PNPDYRK1ATYMSMAPT | |
| SCHEMBL3241710 | 0.65 | PNP (0.39) | QTRT1PNPDYRK1ATYMSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350191-B9 | NUCLEOTIDE ANALOGS | UNIV CALIFORNIA (US) | 2021-12-22 | — | — | EP | claimed |
| EP-3875462-A1 | NUCLEOTIDE ANALOGS | The Regents of The University of California (US) | 2021-09-08 | — | — | EP | claimed |
| EP-3350191-B1 | NUCLEOTIDE ANALOGS | UNIV CALIFORNIA (US) | 2021-05-12 | — | — | EP | claimed |
| EP-3350191-A1 | NUCLEOTIDE ANALOGS | The Regents of the University of California (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048956-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2009120358-A1 | OLIGOMER-NITROGENOUS BASE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-10-01 | — | — | WO | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| US-5641763-A | N-phosphonylmethoxyalkyl derivatives of pyrimdine and purine bases and a therapeutical composition therefrom with antiviral activity | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-06-24 | — | — | US | claimed |
| US-5631259-A | PURINE BASE DERIVATIVES FOR NUCLEOSIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0269947-B2 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1996-10-16 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0472648-A4 | CROSSLINKING OLIGONUCLEOTIDES | — | 1992-09-16 | — | — | EP | claimed |
| US-5142051-A | Viricides special for mutants of herpes viruses | CESKOSLOVENSKA AKADEMIE VED (CS) | 1992-08-25 | — | — | US | claimed |
| EP-0472648-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1992-03-04 | — | — | EP | claimed |
| WO-1990014353-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1990-11-29 | — | — | WO | claimed |
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-0472648-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1990014353-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | IL2, IL2RA, CD22 | QTRT1 3555/4885PNP 4686/4885DYRK1A 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.